New Modeling Reveals High Societal Value Of Early Alzheimer’s Care

TL;DR

For listenersOffer from Amazon

Turn quiet afternoons into listening time

• Thousands of audiobooks, podcasts and originals
• Listen on your phone, tablet or Echo — also offline
• Cancel anytime

Try Audible free →Free trial for new members

As an affiliate, we earn on qualifying purchases.Hide

A USC Schaeffer Center model estimates that donanemab could generate $104,900 in lifetime societal value per person when used at the timing modeled in a clinical trial. Starting treatment two years earlier raises the estimate to $138,300, though the model excludes drug, screening and monitoring costs and relies on assumptions about how long treatment benefits last.

Researchers at the USC Schaeffer Center for Health Policy & Economics estimate that starting the Alzheimer’s drug donanemab two years earlier could raise its modeled lifetime societal value by 32%, from $104,900 to $138,300 per person. The study, published Oct. 7 in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association, projects health and economic benefits; it does not subtract the costs of the drug or the screening and monitoring needed to provide treatment.

The researchers used a dynamic microsimulation model to estimate outcomes for a group resembling participants in a pivotal Phase 3 trial. They compared treatment at the trial’s timing, treatment begun two years earlier but still after symptoms typically emerge, and no treatment. For both treatment scenarios, the model assumed a 29% slowing of disease progression, matching the trial result for donanemab versus placebo after 18 months.

Compared with no treatment, people receiving donanemab at the trial timing were projected to live about 0.3 years longer, spend one fewer year with severe dementia, gain 0.37 disability-free years and spend 0.63 additional years in the community. The model assigned these gains a lifetime value of $104,900 per person: $52,300 from improved health-related quality of life, $23,800 from reduced unpaid caregiving and $22,200 in medical cost offsets, largely accruing to Medicaid. It also estimated annual Medicaid costs would fall by about $1,640, or 13%.

With treatment starting two years earlier, the estimated lifetime value rose to $138,300 per person. A separate scenario that incorporated potentially stronger treatment effects suggested a value of $179,400, 71% above the trial-timing estimate. These are modeled estimates, not observed savings or guaranteed outcomes. The analysis also explored a conservative case in which treatment effects last four years rather than for the patient’s remaining lifetime: estimated value fell to $49,100 for trial-timing treatment and $56,400 for earlier treatment.

Earlier Diagnosis Could Change Treatment Value

The findings address a practical question for health systems and families: whether identifying Alzheimer’s earlier could allow eligible patients to begin a disease-slowing treatment sooner, while preserving more time with less severe impairment. The model suggests potential benefits extend beyond patients’ health-related quality of life to unpaid care partners and public programs that pay for some dementia-related care.

The estimates do not establish that earlier treatment will produce those gains for every patient, or that it will save money overall. The authors did not include the drug, screening or monitoring costs in their value calculation. Those expenses matter when policymakers, insurers and patients weigh access, affordability and the resources required to diagnose and treat people earlier.

The report places the question in a substantial economic setting: Alzheimer’s and related dementias are estimated to cost the United States $818 billion in 2026, with costs expected to grow as the population ages. The study offers one model-based way to consider possible long-term benefits, rather than a full accounting of what broader treatment access would cost.

Diagnosis Delays Shape the Model

The researchers report that Alzheimer’s is diagnosed, on average, 3.5 years after symptoms first appear. That gap is relevant because the treatment scenarios compare starting donanemab at the trial timing with starting it two years earlier, after symptoms would usually have begun. The analysis does not model treatment before symptoms.

Donanemab, marketed as Kisunla, targets amyloid plaques in the brain. The source report says such treatments appear more effective when started earlier in the disease course, while access has faced limits related to coverage, cost and the work of identifying and monitoring eligible patients. New diagnostic tools may affect that process: the report points to blood-based biomarker tests approved by the FDA in the preceding year and newer digital cognitive assessments.

The estimates were generated using the Schaeffer Center’s model developed for the federally funded U.S. Cost of Dementia Project. The researchers drew on national health surveys and dementia-progression studies to project lifetime cognitive status and related outcomes. Their model uses trial-based evidence for donanemab’s effect, while projecting those effects beyond the trial period under specified assumptions.

“Our research suggests that investments in early detection could help ensure that patients start treatments when they’re more likely to provide the greatest benefit to patients and society.”

— Jack Chapel, lead author, USC Schaeffer scholar and assistant research professor at the USC Price School of Public Policy

Costs and Long-Term Effects Remain Open

The estimates depend on assumptions about how much donanemab slows disease progression and how long that effect persists. Because the treatments are new, the researchers say the duration of benefit is uncertain. Their four-year-effects scenario cut the estimated value by about half compared with the main trial-timing estimate, although earlier treatment still produced a higher modeled value in that scenario.

The analysis does not establish the actual lifetime effect for individual patients, the real-world cost of earlier diagnosis and treatment, or whether access barriers can be overcome. It also does not include drug, screening and monitoring expenses in the reported societal value. The source material does not provide a patient-level prediction or a recommendation for a particular person; treatment decisions require clinical assessment by qualified health professionals.

Real-World Evidence Will Test Projections

The study’s estimates can inform discussion of how diagnosis timing, treatment access and dementia-care spending fit together, but they are projections rather than a measured result of a broad early-treatment program. Further evidence on the duration of treatment effects and outcomes when therapy begins earlier would help test the model’s assumptions.

Researchers also modeled hypothetical future drugs: a treatment slowing progression by 50% was assigned a lifetime societal value of $208,700 to $276,700, depending on start time, while a treatment that halted progression was assigned a range of $530,000 to $648,300. Those figures describe modeled scenarios, not available treatment results. The source report notes that more than 150 Alzheimer’s drugs are in clinical testing; how those candidates perform, and what they would cost, remains to be seen.

Key Questions

What did the researchers estimate?

They modeled the lifetime health and economic value of donanemab under different treatment-start scenarios. The main estimate was $104,900 per person at the trial timing and $138,300 when treatment began two years earlier.

Does the $138,300 estimate include the cost of treatment?

No. The reported value reflects modeled health and economic benefits but excludes the costs of the drug, screening and monitoring needed to deliver treatment.

Was earlier treatment shown to benefit every patient?

No. These are population-level model estimates based on trial findings and assumptions, not observed outcomes or a guarantee for an individual. A qualified health professional can discuss treatment decisions based on a person’s circumstances.

Why does the duration of treatment effects matter?

The main projections consider benefits over a patient’s lifetime, but how long donanemab’s effects last is uncertain. In a scenario limiting the effect to four years, the estimated value was lower, though the model still assigned more value to earlier treatment.

Source: rss